Semaglutide vs Tirzepatide vs Retatrutide: The 2026 GLP-1 Decision Guide

In four years, GLP-1 weight-loss peptides have gone from niche diabetes drugs to one of the most-researched compound classes in pharmacology. The progression has been remarkably linear: each generation outperforms the last on weight loss, with mostly similar safety profiles.

If you're trying to understand the differences between semaglutide, tirzepatide, and retatrutide — three compounds you'll see discussed constantly — this guide breaks them down on the metrics that actually matter for research decisions.

You can also see live vendor pricing for all three side by side.

TL;DR — Generational Improvements

Compound	Mechanism	Approval	Mean weight loss	Trial duration
Semaglutide	GLP-1 agonist	FDA-approved	~15%	68 weeks
Tirzepatide	GLP-1 + GIP dual agonist	FDA-approved	~22.5%	72 weeks
Retatrutide	GLP-1 + GIP + Glucagon triple agonist	Phase 3	~24%	48 weeks

The pattern is clear: each generation adds receptor targets and produces more weight loss. The question is whether the additional mechanisms also add risk.

Generation 1: Semaglutide

Brand names: Ozempic (diabetes), Wegovy (weight loss)
Mechanism: Selective GLP-1 receptor agonist
FDA status: Approved for type 2 diabetes (2017) and weight loss (2021)

Semaglutide was the breakthrough that made GLP-1 weight-loss research broadly accessible. It works through a single receptor — the GLP-1 receptor — which slows gastric emptying, reduces appetite, and improves insulin sensitivity.

Key efficacy data: The STEP-1 trial (Wilding et al., NEJM 2021) showed mean 14.9% weight loss at 68 weeks vs 2.4% on placebo, in 1,961 participants without diabetes.

Side effect profile: GI-dominant — nausea, vomiting, diarrhea, constipation, and reduced appetite. Most side effects peak during dose escalation and improve over 8–12 weeks. Less common but more serious: pancreatitis, gallbladder disease, and (in rodent models) thyroid C-cell tumors.

Practical reality: The deepest safety dataset of the three compounds. If you want the option with the most published human data, semaglutide is the conservative choice. Read the full semaglutide profile.

Generation 2: Tirzepatide

Brand names: Mounjaro (diabetes), Zepbound (weight loss)
Mechanism: Dual GLP-1 + GIP receptor agonist
FDA status: Approved for type 2 diabetes (2022) and weight loss (2023)

Tirzepatide added a second receptor — GIP (glucose-dependent insulinotropic polypeptide). The mechanistic rationale: GIP activation in the context of GLP-1 activation appears to amplify weight loss while also improving insulin sensitivity beyond what GLP-1 alone achieves.

Key efficacy data: SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed mean 22.5% weight loss at 72 weeks at the highest dose, in 2,539 participants without diabetes. That's a meaningfully larger effect than semaglutide produced in comparable trials.

Side effect profile: Similar to semaglutide — GI-dominant, with the same dose-escalation pattern. Some research suggests slightly worse GI tolerability at equivalent effective doses, though comparisons are difficult.

Practical reality: As of 2026, tirzepatide is the new default for weight-loss research. Better efficacy than semaglutide, similar safety profile, growing human dataset. Read the full tirzepatide profile.

See cheapest tirzepatide vendors or compare semaglutide vs tirzepatide directly.

Generation 3: Retatrutide

Brand name: None yet (research compound, late Phase 3)
Mechanism: Triple agonist — GLP-1 + GIP + Glucagon receptors
FDA status: Phase 3 trials ongoing as of 2026

Retatrutide is the current frontier. It adds a third receptor: glucagon. The mechanistic rationale is unusual — glucagon receptor activation increases energy expenditure (literally, calorie burn at rest) on top of the appetite-suppression effects from GLP-1 and GIP. The combination is a kind of "dual lever" approach: eat less AND burn more.

Key efficacy data: Phase 2 results (Jastreboff et al., NEJM 2023) showed mean 24.2% weight loss at 48 weeks at the highest dose. Notably, this was at 48 weeks vs 72 for the comparator trials — suggesting the effect size could be even larger at full duration.

Side effect profile: GI side effects similar to predecessors. The new wrinkle: glucagon agonism can theoretically affect liver fat and glucose homeostasis, areas where Phase 3 data will clarify the long-term picture.

Practical reality: Retatrutide is currently a research compound, not yet FDA-approved. The available human data is from Phase 2 trials (limited but high quality). Most "retatrutide" sold by research vendors comes from generic chemistry rather than from licensed pharmaceutical sources — this means vendor verification matters even more than for the approved compounds.

Read the full retatrutide profile. See cheapest retatrutide vendors.

How Should You Choose?

Three practical paths depending on your research question:

Path A: "I want the deepest safety dataset"

Choose: Semaglutide

You're trading some efficacy for the largest body of human data. This is the right answer if your research question prioritizes safety profile depth, or if you'll be tracking outcomes over a long horizon where unknowns matter.

Path B: "I want the best evidence-backed efficacy currently available"

Choose: Tirzepatide

This is the current sweet spot in 2026 — better efficacy than semaglutide, similar safety, FDA-approved for weight loss, and increasingly the default in published research. Most researchers asking "which one" should pick this.

Path C: "I want the frontier"

Choose: Retatrutide

You're accepting more uncertainty in exchange for the largest effect size and the most novel mechanism. Reasonable choice for researchers who follow the literature closely and who select vendors carefully. Bad choice for someone new to the category — too many moving parts, including vendor verification, dosing protocols, and unresolved long-term safety questions.

Cost Comparison

This is where vendor choice dominates.

Pharmacy-grade semaglutide and tirzepatide (Ozempic, Wegovy, Mounjaro, Zepbound) are extremely expensive — often $1,000+ per month at retail. Insurance coverage varies wildly.

Research-grade alternatives from peptide vendors are dramatically cheaper but require careful vendor verification. As of Q2 2026:

Semaglutide: Roughly $80–250 for a 5–10mg vial from a verified vendor
Tirzepatide: Roughly $100–350 for a 10–20mg vial from a verified vendor
Retatrutide: Roughly $200–500 for a 10mg vial from a verified vendor

The price-to-effect ratio currently favors tirzepatide for most researchers — better efficacy than semaglutide at not-much-higher cost.

Live pricing is on:

Vendor Verification Is Critical for This Class

Quality issues with research-grade GLP-1s are documented. Specifically:

Underdosing. Vials labeled 10mg containing closer to 7-8mg actual peptide
Wrong compound. Tirzepatide vials containing semaglutide (or worse, generic GLP-1 fragments)
Contamination. Endotoxin levels above the threshold for safe use
Mislabeling. Compound names obfuscated as "GLP-1SG" or "Compound 21" for payment-processor reasons (this isn't necessarily fraud, but it does mean you need to verify what you actually got)

Three minimum checks before ordering any GLP-1:

Public, named-lab COA linked from the product page. The COA should show purity ≥98%, identity confirmation by mass spec or HPLC, and a batch number that matches the vial.
LAL endotoxin testing if available. This is the gold-standard signal that the vendor cares about injectable safety.
Recent Trustpilot reviews mentioning the specific compound. If 95% of reviews are about BPC-157 and there's nothing specific to semaglutide or tirzepatide, you don't have signal on that compound.

We rate every vendor on these factors. See our trust methodology and the best vendors for retatrutide page for current top-rated options.

What About CagriSema, Mazdutide, and Future Compounds?

A few honorable mentions in the GLP-1 lineup:

CagriSema is the combination of cagrilintide (an amylin analog) and semaglutide. The rationale is that amylin and GLP-1 hit different satiety pathways, so combining them produces additive effects. Phase 3 data is positive but marginal vs tirzepatide alone. Not yet a clear winner.

Mazdutide is Eli Lilly's GLP-1 + glucagon dual agonist (no GIP), targeting Asian markets primarily. Late-stage trials show ~15-18% weight loss — between semaglutide and tirzepatide. Limited Western availability.

Cagrilintide alone is also being studied as a monotherapy. Lower efficacy than the dual/triple agonists but a different mechanism, which makes it interesting for combination protocols.

For most researchers, these are interesting but not yet the clearest path. Tirzepatide for proven efficacy, retatrutide for the frontier, semaglutide for the safety dataset.

Bottom Line

If you're trying to choose one:

Default answer: Tirzepatide. Best evidence-backed efficacy currently available, FDA-approved, growing dataset.
Conservative answer: Semaglutide. Deepest safety data, slightly less efficacy.
Frontier answer: Retatrutide. Largest effect size, but vendor verification and long-term safety still developing.

If you're starting research from scratch and aren't sure which to pick, tirzepatide is the right answer for most people in 2026.

Always verify the vendor before ordering any of these. The compounds are well-studied; the vendors selling them are not equally trustworthy.

When you're ready to compare current pricing:

For research use only. Not medical advice. Always consult a qualified healthcare provider before working with any research compound.